Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019Open in a New Window

LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the presentation of PXL065 Phase 1a results during a poster presentation session at the Liver Meeting® 2019 hosted by the American Association for the Study of Liver Diseases (AASLD). In the poster presentation, PXL065 was observed to hav

 

NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019Open in a New Window

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) today announced promising results from its pre-clinical collaboration1 with The University of Texas MD Anderson Cancer Center. The research, which evaluated first-in-class radioenhancer NBTXR3 activated by radiation therapy in combination with anti-PD-1 and anti-CTLA-4 immune checkpoint inhibitors, was presented last week at the 2019 Annual Meeting of the

 

CORRECTING and REPLACING Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 OutlookOpen in a New Window

CLEARWATER, Fla.--(BUSINESS WIRE)--In the "2019 Financial Outlook" section, the fifth bulleted item should read: GAAP net loss in the range of $20.3 million to $19.8 million... (instead of GAAP net loss in the range of $20.3 million to $219.8 million...). The corrected release reads: APYX MEDICAL CORPORATION REPORTS THIRD QUARTER OF 2019 FINANCIAL RESULTS AND UPDATES FISCAL YEAR 2019 OUTLOOK Advanced Energy Sales of $6.1 million in Q3, up 104% year-over-year Apyx Medical Corporation (NASDAQ:APY

 

Sage Therapeutics to Present at the Stifel 2019 Healthcare ConferenceOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $sage #SageRx--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019, at 10:20 a.m. EST in New York, NY. A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A

 

Global Design Contest Awards ULiSSES™ Medical Device Grand PrizeOpen in a New Window

SAN ANTONIO--(BUSINESS WIRE)--Vascular Perfusion Solutions accepts the grand prize in the "Create the Future" Design Contest for the creation of the ULiSSES™ medical device.

 

Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology DayOpen in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)--Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

 

Castle Biosciences Reports Third Quarter 2019 ResultsOpen in a New Window

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences today announced its financial results for the third quarter and nine months ended September 30, 2019.

 

CONMED Corporation to Present at the Jefferies London Healthcare ConferenceOpen in a New Window

UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NASDAQ: CNMD) today announced that Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Jefferies London Healthcare Conference at 9:20 a.m. GMT (4:20 a.m. ET) on Wednesday, November 20, 2019 in London, UK. A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.conmed.com and will be available for replay following the event. About CONMED Corporatio

 

Endologix, Inc. to Present at the Stifel Healthcare ConferenceOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John Onopchenko, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, will present at the Stifel Healthcare Conference at 3:00 p.m. ET on Tuesday, November 19, 2019 in New York, NY. A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.endologix.com and will b

 

Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European UnionOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

 

United States Automated Insulin Delivery System Market Report 2019 - Prospects, Trends Analysis, Market Size and Forecasts up to 2025 - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "United States Automated Insulin Delivery System Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering. The report on the United States automated insulin delivery system market provides a detailed analysis of segments in the market based on disease type, and end user. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the U

 

Global Clinical Study Sponsors and Clinical Research Organizations Gather for the “Era of Life Science Transformation” at Medidata NEXT NYC 2019Open in a New Window

NEW YORK--(BUSINESS WIRE)-- #Medidata--Medidata NEXT NYC, the premier conference on the digital transformation of life sciences, is set for November 12-13 at Spring Studios in New York City. Medidata NEXT NYC, the centerpiece of Medidata’s global conference series, will feature keynote addresses by healthcare industry visionaries, including: Tarek Sherif and Glen de Vries, co-CEOs and founders, Medidata®, part of Dassault Systèmes Bernard Charlès, Vice Chairman and CEO, Dassault Systèmes Siddhartha Mukherj

 

CORRECTING and REPLACING Positive Data from First Clinical Study of RUC-4, a Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor Designed for First Point-of-Contact STEMI Therapy, Presented at AHA 2019 Late-Breaking Science SessionOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Data from a completed clinical study show RUC-4 provided a potent, rapid, and sustained platelet inhibition effect in stable CAD patients w/aspirin.

 

Oragenics, Inc. SVP of Discovery Research, Martin Handfield, Ph.D. to Be Featured Speaker at the International Conference on Microbial Research and ApplicationsOpen in a New Window

TAMPA, Fla.--(BUSINESS WIRE)--MARTIN HANDFIELD, PH.D. TO BE FEATURED SPEAKER AT THE INTERNATIONAL CONFERENCE ON MICROBIAL RESEARCH AND APPLICATIONS

 

Oticon Xceed and Oticon RemoteCare Receive CES 2020 Innovation Honors for Breakthrough Hearing TechnologyOpen in a New Window

SOMERSET, N.J.--(BUSINESS WIRE)-- #awards--For the fourth consecutive year, the Consumer Technology Association (CTA) has recognized Oticon for their excellence in developing breakthrough hearing technology. Oticon Xceed, the world’s most powerful hearing aid, was named a CES 2020 Innovation Awards Honoree in the Health & Wellness category, while Oticon RemoteCare, a new e-health solution that streamlines patient-provider aftercare services, was recognized as an honoree in the Tech for a Better World

 

The Rite Aid Foundation Donates $75,000 to Support Wildfire Relief Efforts in CaliforniaOpen in a New Window

CAMP HILL, Pa.--(BUSINESS WIRE)--The Rite Aid Foundation announced today a $75,000 donation, which will be distributed to the American Red Cross Los Angeles Region and American Red Cross Northern California Coastal Region to support wildfire relief efforts. “The devastating and destructive fires that have wreaked havoc in California during the past few weeks have forced thousands of residents up and down the state to flee their homes and destroyed more than a quarter-million acres of land,” sai

 

Mesa Labs Acquires Gyros Protein TechnologiesOpen in a New Window

LAKEWOOD, Colo.--(BUSINESS WIRE)--Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a diversified supplier of quality control instruments and consumables to highly regulated markets today announced the acquisition of Gyros Protein Technologies Holding AB (“GPT”). GPT is headquartered in Uppsala, Sweden and is a leading provider of Immunoassay and Peptide Synthesis solutions that accelerate the discovery, development and manufacturing of biotherapeutics. The acquisiti

 

Battelle Celebrates Veterans with Donations to Honor Flight Columbus, National Veterans Memorial and MuseumOpen in a New Window

COLUMBUS, Ohio--(BUSINESS WIRE)--They all gave some. Some gave all. As America celebrates Veterans Day to honor those brave men and women who put their lives on the line in the United States Armed Forces, Battelle is honoring its 90-year commitment to making a positive impact on society by supporting two premier organizations for veterans. Battelle’s donation of $70,000 will fully support an Honor Flight Columbus trip to Washington D.C. next May in which about 100 veterans and 50 volunteers wil

 

ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019Open in a New Window

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a treatment for dementia-related psychosis at the upcoming 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting. Webcast Details Date: Wednesday, December 4, 2019 Time: 7:00 p.m. Pacific Time The live webcast will include a presentation of the results

 

Echosens at VA’s National Veterans Small Business Engagement Meeting: Demonstrating FibroScan Benefits for Early Detection and Monitoring of Liver DiseaseOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)-- #NAFLD--Echosens at VA’s National Veterans Small Business Engagement Meeting: Demonstrating FibroScan Benefits for Early Detection & Monitoring Liver Disease

 

Leo Lens Technology Selected as Finalist for Connect’s 2019 Most Innovative New Product AwardsOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Leo Lens Technology Selected as Finalist for Connect’s 2019 Most Innovative New Product Awards

 

Universal Display Corporation Announces Participation at Upcoming ConferencesOpen in a New Window

EWING, N.J.--(BUSINESS WIRE)---- $OLED #OLED--Universal Display Corporation today announced its participation in upcoming investor and industry conferences.

 

The New 2020 Report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Gives Highest Evidence Rating to Endobronchial Valves, including the Zephyr Valve, for Treatment of Emphysema / COPDOpen in a New Window

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COPD--GOLD’s evidence “A” rating affirms that endobronchial valves, like the Zephyr Valve, are a proven, viable treatment for COPD/Emphysema

 

 Airflow Sleep, a Sleep Solutions and Advocacy Company, Launches to Fight the Sleep EpidemicOpen in a New Window

WELLESLEY, Mass.--(BUSINESS WIRE)--Airflow Sleep, a sleep solutions and advocacy company, launches to fight the sleep epidemic.

 

Millendo Therapeutics to Present at the Stifel 2019 Healthcare ConferenceOpen in a New Window

ANN ARBOR, Mich.--(BUSINESS WIRE)--Millendo Therapeutics to Present at the Stifel 2019 Healthcare Conference.

 

Magenta Therapeutics Presents First Immune Reset Results with Antibody-Drug Conjugate Across Multiple Autoimmune Diseases at ACROpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today reported new data showing successful immune reset with a single dose of its CD45-ADC in models of three autoimmune diseases. These results were presented yesterday at the American College of Rheumatology (ACR) Annual Meeting in Atlanta, Ga. “Millions of patients worldwide live with de

 

Charles River Laboratories to Present at Upcoming Investor ConferencesOpen in a New Window

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories to present at upcoming investor conferences.

 

Newly Published Research Demonstrates Ability of Hologic’s Assay to Detect Mycoplasma Genitalium, “the Silent Epidemic”Open in a New Window

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Mgen--Newly Published Research Demonstrates Ability of Hologic’s Assay to Detect Mycoplasma Genitalium, “the Silent Epidemic”

 

United States Needle-free Diabetes Care Markets 2019-2025 by Insulin Patches, Jet Injectors, Insulin Pens, Insulin Pumps, Insulin Infuser - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "United States Needle-free Diabetes Care Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2025" report has been added to ResearchAndMarkets.com's offering. The country research report on the United States needle-free diabetes care market is a customer intelligence and competitive study of the United States market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the United States

 

New Clinical Results from the Acessa System to be Presented at AAGL Global Congress on Minimally Invasive GynecologyOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)-- #AAGL2019--Acessa Health's ProVu® System for treatment of uterine fibroids will be focus of positive clinical data presentations at AAGL

 

Veterans With Type 2 Diabetes Achieve Rapid Health Improvements in Virta Health Partnership With VAOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Veterans living with type 2 diabetes achieve rapid health improvements in the Virta Health partnership with the U.S. Department of Veterans Affairs

 

Sir Andrew Witty Named UnitedHealth Group PresidentOpen in a New Window

MINNETONKA, Minn.--(BUSINESS WIRE)--UnitedHealth Group has appointed Andrew Witty UnitedHealth Group president, in addition to serving as Optum's chief executive officer.

 

EMist to Reveal a Breakthrough Disinfectant SprayerOpen in a New Window

FORT WORTH, Texas--(BUSINESS WIRE)--EMist announced today they will introduce the EPIX360, a revolutionary hand-held disinfectant sprayer, at ISSA 2019. The EPIX360 is an electrostatically charged sprayer that provides more coverage, less waste, and better results. The EPIX360 is a powerful, efficient, and cost-effective disinfectant application system. The patented system places an appropriate electrostatic charge to disinfectant as it leaves the spray nozzle, giving each droplet a powerful at

 

Motus GI Announces EXPEDITE Study Initiated by Boston Medical Center to Evaluate Clinical Effectiveness of Pure-Vu® System for Improving Bowel Preparation RatesOpen in a New Window

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Boston Medical Center (BMC) has initiated the EXPEDITE clinical study to evaluate the effectiveness of the Pure-Vu System on bowel preparation rates. “There is a gr

 

VBI Vaccines to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019 Society for Neuro-Oncology (SNO) Annual MeetingOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the Company’s abstract titled, “Interim Results of the Extension Phase of a Phase I/IIa Trial of a Therapeutic CMV Vaccine Against Recurrent Glioblastoma (GBM)” was accepted for poster presentation at the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Onc

 

Oncternal Therapeutics to Present at Stifel Healthcare ConferenceOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT. A live webcast of the presentation will be available online via a link from the inv

 

Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment OutcomesOpen in a New Window

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a patient case series at the American College of Rheumatology (ACR) Annual Meeting illustrating that the addition of methotrexate to a course of therapy with KRYSTEXXA® (pegloticase injection) may help more people with chronic gout refractory to conventional therapies – also known as uncontrolled gout – achieve response to treatment. In addition, Horizon will present data describing the inflamma

 

UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract CancersOpen in a New Window

NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an exclusive worldwide1 license agreement with Agenus Inc (Nasdaq:AGEN) to develop and commercialize zalifrelimab (AGEN1884, anti-CTLA-4 antibody) via intravesical delivery in combination with UGN-201 for the treatment of urinary tract cancers. This combination is based on encou

 

United States Home Rehabilitation Products and Services Market Report 2019: Prospects, Trends Analysis, Market Size and Forecasts up to 2024 - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "United States Home Rehabilitation Products and Services Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The country research report on United States home rehabilitation products and services market is a customer intelligence and competitive study of the United States market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indi

 

United States Legal Marijuana Market Report 2019-2024: Prospects, Trends Analysis, Market Size and Forecasts - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "United States Legal Marijuana Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The country research report on United States legal marijuana market is a customer intelligence and competitive study of the United States market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the United States market. Also, factors th

 

United States Smart Syringes Market Report 2019-2024: Prospects, Trends Analysis, Market Size and Forecasts - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "United States Smart Syringes Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The country research report on the United States smart syringes market is a customer intelligence and competitive study of the United States market. The report on United States smart syringes market provides a detailed analysis of segments in the market based on therapeutic categories, application, and en

 

Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End ResultsOpen in a New Window

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals today announced that it will host a Fiscal 2019 year end webcast and conference call on November 25, 2019, at 4:30 p.m. EST

 

Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019Open in a New Window

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305, Enanta’s lead Farnesoid X receptor (FXR) agonist, will be presented today at The Liver Meeting® 2019, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 8-12, 2019 in Boston. EDP-305 po

 

Healthcare at a Crossroads: What’s the Path Forward?Open in a New Window

RYE, N.Y.--(BUSINESS WIRE)--Gabelli Funds and Columbia Business School are hosting a unique healthcare symposium to provide a platform for industry and academic leaders to address critical issues facing the healthcare industry today. The panelists consist of executives from the healthcare ecosystem, including providers, payers, pharmaceutical companies, pharmacy benefit managers, wholesalers and academia. Specifically, the symposium will address the 2020 election and its implications for the he

 

United States Bio-MEMS Market Report 2019: Prospects, Trends Analysis, Market Size and Forecasts up to 2024 - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "United States Bio-mems Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The country research report on United States Bio-MEMS market is a customer intelligence and competitive study of the United States market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the United States market. Also, factors that are driving

 

United States Medical Cameras And Microscopes Market Report 2019: Prospects, Trends Analysis, Market Size and Forecasts up to 2024 - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "United States Medical Cameras And Microscopes Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering. The country research report on United States medical cameras and microscopes market is a customer intelligence and competitive study of the United States market. Moreover, the report provides deep insights into demand forecasts, market trends, and, micro and macro indicators in the United

 

New Data Uncover Deeper Insight into Tebentafusp (IMCgp100) Clinical Activity in Patients with Advanced Melanoma, Including UvealOpen in a New Window

OXFORDSHIRE, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md.--(BUSINESS WIRE)--Immunocore Limited, a leading T cell receptor (TCR) biotechnology company, presented new findings from its Phase 1/2 tebentafusp (IMCgp100) clinical trial programme demonstrating a correlation between treatment-induced immune response and improvement in overall survival and tumour shrinkage, in patients with advanced uveal and cutaneous melanoma. The new analyses from two clinical trials (IMCgp100-101, IMCgp100-102) wer

 

Goldfinch Bio Presents Novel Process for Developing Human iPSC-Derived Organoids at Scale at the American Society of Nephrology Kidney Week 2019 Annual MeetingOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, presented a novel approach to producing human induced pluripotent stem cell (iPSC)-derived organoids at scale in an oral presentation on November 9th at the American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting in Washington, D.C. “Human iPSC-derived organoids are emerging models that c

 

Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019Open in a New Window

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Company’s inhaled PDGFR inhibitor for the treatment of pulmonary arterial hypertension (PAH), have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2019

 

Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health MarketOpen in a New Window

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis in Animal Health Market

 

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Advanced Hepatocellular CarcinomaOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review BMS’s Application for Opdivo Plus Yervoy Combination for Patients with Previously Treated Advanced HCC

 

Gynesonics Announces Full Launch of New Sonata 2 System at 48th AAGL Global CongressOpen in a New Window

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today the full launch of the Sonata® 2 System in the United States and Europe at the American Association of Gynecologic Laparoscopists (AAGL) Conference, in Vancouver, BC, Canada, from November 10-13. The Sonata System is the world’s first and only transcervical fibroid ablation system that combines the first ever

 

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect